ストックスクリーナーアプリを入手
3.405
0.60%
0.015
Editas Medicine Inc (EDIT) 最新ニュース
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Editas Medicine (NASDAQ:EDIT) Downgraded by Wall Street Zen to Sell - MarketBeat
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Editas Medicine, Inc. Files Form 8-K Announcing Changes in Certifying Accountant – April 2026 - Minichart
Editas Medicine appoints PwC as new auditor, dismisses Ernst & Young - Investing.com India
Editas Medicine appoints PwC as new auditor, dismisses Ernst & Young By Investing.com - Investing.com South Africa
Audit shakeup at Editas Medicine (NASDAQ: EDIT) as PwC replaces Ernst & Young - Stock Titan
Growth Value: How correlated is Editas Medicine Inc to the S P500Sell Signal & Safe Capital Investment Plans - baoquankhu1.vn
Price Action: Will Editas Medicine Inc benefit from sector rotation2026 Trade Ideas & Weekly High Conviction Ideas - baoquankhu1.vn
Editas Medicine shares edge higher after Q4 earnings and revenue top estimates - MSN
EDIT Should I Buy - Intellectia AI
Gene Editing Market Set to Boom Rapidly by 2033 |CRISPR - openPR.com
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y - Eastern Progress
Volume Report: Can Editas Medicine Inc ride the EV waveGold Moves & Low Risk Entry Point Guides - baoquankhu1.vn
Editas Medicine Inc Stock: Genome Editing Pioneer Faces Key Milestones in Competitive Biotech Landsc - AD HOC NEWS
Fundamentals Check: Will Editas Medicine Inc benefit from sector rotationGap Up & Risk Managed Investment Signals - baoquankhu1.vn
Setup Watch: Does Editas Medicine Inc have strong fundamentals2026 Top Gainers & Expert-Curated Trade Recommendations - baoquankhu1.vn
Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program - MSN
EDIT PE Ratio & Valuation, Is EDIT Overvalued - Intellectia AI
Editas Medicine Inc Stock: Gene Editing Pioneer Faces Clinical and Market Hurdles in Biotechnology L - AD HOC NEWS
Editas Medicine wins CRISPR patent ruling from USPTO - StreetInsider
USPTO Ruling Impacts Editas Medicine CRISPR IP Position - TipRanks
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference - Bitget
USPTO Reaffirms Broad Institute’s Patents in CRISPR/Cas9 Dispute - geneonline.com
CRISPR patent win bolsters Editas Medicine (NASDAQ: EDIT) IP estate - Stock Titan
[SCHEDULE 13G/A] Editas Medicine, Inc. Amended Passive Investment Disclosure - Stock Titan
EDITAS MEDICINE Operating Margin %: -56.65% | Fairly Valued - GuruFocus
MACD Signal: Can Editas Medicine Inc maintain sales growthEarnings Summary Report & Community Consensus Stock Picks - baoquankhu1.vn
How correlated is Editas Medicine Inc to the S P5002026 Pullback Review & High Yield Equity Trading Tips - baoquankhu1.vn
Q2 EPS Estimates for Editas Medicine Decreased by Analyst - MarketBeat
Zacks Research Weighs in on Editas Medicine FY2028 Earnings - MarketBeat
If You Invested $1,000 in Editas Medicine Inc (EDIT) - Stock Titan
Editas Medicine, Inc. Trade Ideas — LS:A2AC4K - TradingView
RSI Check: Can Editas Medicine Inc outperform in the next rally2026 EndofMonth & High Accuracy Investment Signals - baoquankhu1.vn
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), DocGo (DCGO) and Editas Medicine (EDIT) - The Globe and Mail
Institution Moves: Can Editas Medicine Inc disrupt its industry2026 News Drivers & Technical Pattern Based Buy Signals - baoquankhu1.vn
Editas Medicine (EDIT) Stock: 5-Year Valuation Drop & Recent Pipeline ChallengesNews and Statistics - IndexBox
Is Editas Medicine Going to $0? - The Globe and Mail
Can Editas Medicine Inc grow without external funding2026 Macro Impact & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT) and Ascend Wellness Holdings LLC (OtherAAWH) - The Globe and Mail
Is Editas Medicine Headed Toward Zero? - Bitget
Editas Medicine (EDIT) grants 292,856 stock options to chief scientific officer - Stock Titan
Editas Medicine (EDIT) CEO awarded 1.02M stock options vesting over 4 years - Stock Titan
Editas Medicine Details In Vivo CRISPR Plan, Targets Year-End Human Proof-of-Concept for EDIT-401 - MarketBeat
Editas Medicine at Barclays Conference: Strategic Focus on CRISPR Innovation - Investing.com Canada
Regulatory Disruptions at FDA Threaten Editas Medicine’s Gene-Editing Timelines and Commercial Prospects - TipRanks
Editas Medicine (EDIT) Receives Upgrade to 'Buy' from Jones Trad - GuruFocus
Editas Medicine (NASDAQ:EDIT) Upgraded at JonesTrading - MarketBeat
Jones Trading upgrades Editas Medicine stock rating on gene therapy progress - Investing.com Canada
1.72%
0.94%
大文字化:
|
ボリューム (24 時間):